Novocure Ltd. has announced the forthcoming presentation of final secondary endpoint results from the Phase 3 PANOVA-3 trial. This trial evaluates the use of Tumor Treating Fields (TTFields) therapy in conjunction with gemcitabine and nab-paclitaxel for patients with unresectable, locally advanced pancreatic cancer. The data will be shared as a late-breaking abstract during an oral presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, scheduled to occur from July 2 to July 5 in Barcelona, Spain. The PANOVA-3 trial demonstrated a statistically significant improvement in median overall survival for patients treated with TTFields, as well as a delay in pain progression and preserved quality of life. TTFields therapy was well-tolerated, with mild to moderate skin adverse events being the most common device-related issues. Novocure plans to submit a premarket application for TTFields therapy to the FDA in the second half of 2025.